EPSTEIN ROBERT S 4
4 · VERACYTE, INC. · Filed May 22, 2026
Research Summary
AI-generated summary of this filing
Veracyte (VCYT) Director Robert S. Epstein Sells 10,000 Shares
What Happened Robert S. Epstein, a director of Veracyte, sold 10,000 shares of Veracyte common stock in an open-market transaction on May 20, 2026. The weighted average sale price was $44.01, producing gross proceeds of approximately $440,129. This was a sale (not a purchase); such transactions are often routine and may have been pre-scheduled.
Key Details
- Transaction date: May 20, 2026 (reported on Form 4 filed May 22, 2026).
- Sale details: 10,000 shares sold; weighted average price $44.01; sale prices ranged from $44.00 to $44.10.
- Proceeds: Approximately $440,129 (gross).
- Plan note: The sale was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Epstein on December 5, 2025 (pre-scheduled sale).
- Shares owned after transaction: Not specified in the provided filing summary.
- Timeliness: Form 4 filed May 22, 2026 — within the typical two-business-day filing window for Form 4s.
Context A Rule 10b5-1 plan lets insiders sell pre-specified amounts on a set schedule and is commonly used to avoid the appearance of trading on inside information; it generally indicates the trades were planned in advance rather than reactive. For retail investors, purchases typically carry more informational weight than routine sales, but this disclosure shows a director reduced holdings under a prearranged plan.
Insider Transaction Report
- Sale
Common Stock
[F1][F2]2026-05-20$44.01/sh−10,000$440,129→ 52,446 total
Footnotes (2)
- [F1]The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on December 5, 2025.
- [F2]Represents weighted average sales price. Sale prices for the transactions range from $44.00 to $44.10. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.